Pathstone Family Office, LLC Incyte Corp Transaction History

Pathstone Family Office, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$67.18 - $84.11 $17,533 - $21,952	261 Added 8.5%	3,332 $267,000
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $203,238 - $254,463	3,071 New	3,071 $205,000
Q1 2021 May 14, 2021	SELL	$76.02 - $100.5 $1,216 - $1,608	-16 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$80.74 - $97.7 $1,291 - $1,563	16 New	16 $1,000
Q3 2019 Nov 13, 2019	SELL	$72.82 - $86.52 $29,127 - $34,608	-400 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$73.52 - $88.7 $29,408 - $35,480	400 New	400 $34,000
Q1 2019 May 14, 2019	SELL	$63.56 - $88.17 $25,424 - $35,268	-400 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$58.5 - $69.94 $21,352 - $25,528	365 Added 1042.86%	400 $25,000
Q3 2018 Nov 09, 2018	BUY	$61.75 - $74.23 $2,161 - $2,598	35 New	35 $2,000

645

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

Stay updated on Pathstone Family Office, LLC with notifications on news.